Oncogene-driven metabolic regulation of Dihydroceramide Desaturase 1 (DES1) converges on GAPDH in matrix-detached conditions

Lambadis, D. L., Franzi, V., Peperno, D. M., Linzer, R. W., Aminov, J., Romero Garcia, H. R., Campanella, C. N., Resnick, A. E., Alvarez, F. A., Allopenna, J. J., et al.

10.64898/2026.06.18.733233 · was preprinted

biomedical

Surfaced because: matches the platform's topic region.

relevance 0.28 openness 0.00 novelty 0.30

Abstract

Deregulation of sphingolipid (SL) metabolism is well-established across many cancers, yet the underlying mechanisms that drive changes in SLs are poorly understood. We previously identified dihydroceramide desaturase 1 (DES1) as a downstream target of HER2 and implicated DES1 as a driver of anchorage-independent survival in breast cancer. In this study, we expand on these results to establish the oncogenic PI3K pathway as a driver of post-translational DES1 activity following cell detachment from the extracellular matrix. PI3K activation of DES1 required glucose uptake and metabolism through both glycolysis and the pentose phosphate pathway. However, it did not require glucose flux into the TCA cycle and was independent of antioxidant capacity of the cell. Moreover, Instead, results identify GAPDH - a point of convergence between glycolysis and PPP - as important for oncogene-driven DES1 activity. Overall, this study defines a novel pathway of DES1 regulation and establishes DES1 as a point of crosstalk between glucose and SL metabolic pathways.

Lifecycle

biorxiv v2 2026-07-08 source ↗

Discussion

No qualifying discussion yet.